Alzheimer’s drug from Eisai and Biogen slows cognitive decline, side-effects in focus

By Deena Beasley

2022.12.01

“All of these amyloid-lowering drugs carry a risk for increased brain hemorrhage,” said Dr. Ronald Petersen of the Mayo Clinic in Rochester, Minnesota. “I think the primary outcomes, the secondary outcomes, the amyloid-lowering is pretty impressive.”

The Alzheimer’s Association said the data confirms the drug “can meaningfully change the course of the disease,” and called on U.S. regulators to approve the company’s application for accelerated approval.